Table 2.
Univariate and multivariate analysis of factors associated with disease-free survival (DFS).
| Factors | No. of non-recurrent cases | No. of recurrent cases | Univariate analysis for DFS | Multivariate analysis for DFS | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| Age (year) | 0.204 | – | – | |||
| <50 | 977 | 77 | 1 [Reference] | |||
| ≥50 | 1,777 | 117 | 0.83 (0.62–1.11) | |||
| BMI (kg/m2) | 0.224 | – | – | |||
| <25 | 2,021 | 135 | 1 [Reference] | |||
| ≥25 | 733 | 59 | 1.21 (0.89–1.64) | |||
| VFA (cm2) | 0.043 | 0.010 | ||||
| <100 | 1,622 | 100 | 1 [Reference] | 1 [Reference] | ||
| ≥100 | 1,132 | 94 | 1.34 (1.01–1.77) | 1.46 (1.10–1.95) | ||
| ASMI (kg/m2) | 0.042 | 0.038 | ||||
| ≥5.7 | 2,287 | 150 | 1 [Reference] | 1 [Reference] | ||
| <5.7 | 467 | 44 | 1.41 (1.01–1.98) | 1.44 (1.02–2.03) | ||
| Menopausal status | 0.354 | – | – | |||
| Pre/peri-menopausal | 1,086 | 83 | 1 [Reference] | |||
| Post-menopausal | 1,668 | 111 | 0.87 (0.66–1.16) | |||
| History of HTN | 0.915 | – | – | |||
| No | 2,046 | 145 | 1 [Reference] | |||
| Yes | 708 | 49 | 0.98 (0.71–1.36) | |||
| History of DM | 0.676 | – | – | |||
| No | 2,530 | 180 | 1 [Reference] | |||
| Yes | 224 | 14 | 0.89 (0.52–1.53) | |||
| Surgery type | < 0.001 | 0.007 | ||||
| Simple mastectomy | 1,742 | 148 | 1 [Reference] | 1 [Reference] | ||
| Breast conservation | 971 | 40 | 0.50 (0.35–0.71) | 0.65 (0.45–0.94) | ||
| Others | 41 | 6 | 1.55 (0.68–3.50) | 2.21 (0.97–5.04) | ||
| Pathological type | 1.168 | – | – | |||
| IDC | 2,019 | 134 | 1 [Reference] | |||
| Others | 735 | 60 | 1.24 (0.91–1.68) | |||
| Pathological node status | < 0.001 | 0.100 | ||||
| Negative | 1,952 | 94 | 1 [Reference] | 1 [Reference] | ||
| Positive | 802 | 100 | 2.56 (1.93–3.39) | 1.41(0.94–2.14) | ||
| Clinical tumor stage | < 0.001 | < 0.001 | ||||
| T0–1 | 1,401 | 53 | 1 [Reference] | 1 [Reference] | ||
| T2 | 1,034 | 76 | 1.91 (1.35–2.72) | 1.50 (0.98–2.28) | ||
| T3–T4 | 319 | 65 | 5.13 (3.57–7.37) | 3.38 (2.01–5.68) | ||
| AJCC stage | < 0.001 | < 0.001 | ||||
| I –II | 1,787 | 69 | 1 [Reference] | 1 [Reference] | ||
| III | 967 | 125 | 3.19 (2.38–4.29) | 1.99 (1.40–2.83) | ||
| Ki67 status | 0.010 | 0.130 | ||||
| <14% | 877 | 45 | 1 [Reference] | 1 [Reference] | ||
| ≥14% | 1,877 | 149 | 1.54 (1.10–2.1) | 0.74 (0.50–1.09) | ||
| Molecular subtypes | < 0.001 | < 0.001 | ||||
| HR+/HER2- | 1,729 | 76 | 1 [Reference] | 1 [Reference] | ||
| HR+/HER2+ | 345 | 18 | 1.19 (0.71–1.98) | 0.94 (0.55–1.60) | ||
| HR-/HER2+ | 350 | 50 | 3.11 (2.17–4.44) | 2.30 (1.55–3.43) | ||
| TNBC | 330 | 50 | 3.34 (2.33–4.77) | 2.79 (1.88–4.16) | ||
| Chemotherapy | 0.002 | 0.117 | ||||
| No | 1,023 | 50 | 1 [Reference] | 1 [Reference] | ||
| Yes | 1,731 | 144 | 1.66 (1.20–2.2) | 0.73 (0.49–1.08) | ||
| Radiotherapy | 0.141 | – | – | |||
| No | 1,254 | 78 | 1 [Reference] | |||
| Yes | 1,500 | 116 | 1.24 (0.93–1.65) | |||
BMI, body mass index; VFA, visceral fat area; ASMI, Appendicular Skeletal Muscle Mass Index; HTN, hypertension; DM, diabetes mellitus; IDC, invasive ductal carcinoma; AJCC, American Joint Committee on Cancer; HR, hormone receptor; HER2, human epithelial growth factor-2; TNBC, triple-negative breast cancer; OS, overall survival; HR, hazard ratio; CI, confidence interval.